Tris blocks Actavis’ ADHD generic

New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Number of pay-for-delay deals remains low, says FTC

7 December 2020 The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

Americas

Federal Circuit rejects ADHD generic drug challenge

8 July 2022 A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.

More on this story

Americas

Number of pay-for-delay deals remains low, says FTC

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

Americas

Federal Circuit rejects ADHD generic drug challenge

8 July 2022 A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.

More on this story

Americas

Number of pay-for-delay deals remains low, says FTC

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

Americas

Federal Circuit rejects ADHD generic drug challenge

8 July 2022 A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.